Metachromin C, a marine-derived natural compound, shows potential in antitumor activity

Int J Med Sci. 2024 Oct 7;21(13):2578-2594. doi: 10.7150/ijms.101037. eCollection 2024.

Abstract

Metachromin C was first isolated from the marine sponge Hippospongia metachromia and has been reported to possess potent cytotoxicity against leukemia cells. However, its antitumor activity and possible mechanisms in pancreatic cancer remain unclear. The effects of Metachromin C on cell viability were estimated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. The compound demonstrated a cytotoxic effect on four pancreatic cancer cell lines (PANC-1, BxPC-3, MiaPaCa-2, and AsPC-1). The significant S phase arrest observed with Metachromin C treatment suggests its impact on DNA replication machinery. Metachromin C might interfere with the binding of Topoisomerase I (TOPO I) to DNA, inhibit TOPO I activity, prevent DNA relaxation, cause DNA damage, and consequently activate the DNA repair pathway. Additionally, anti-migration and anti-invasion abilities of Metachromin C were confirmed using the transwell assay. It also inhibited angiogenesis in human endothelial cells by reducing cell proliferation, migration, and disrupting tube formation. Moreover, Metachromin C dose-dependently inhibited the growth of intersegmental vessels, subintestinal vessels, and the caudal vein plexus in a zebrafish embryo model, confirming its inhibitory effect on new vessel formation in vivo. Taken together, Metachromin C could not only inhibit the growth of pancreatic cancer cells but also act as an anti-angiogenic compound simultaneously.

Keywords: anti-angiogenesis; metachromin C; pancreatic cancer; zebrafish.

MeSH terms

  • Animals
  • Antineoplastic Agents* / pharmacology
  • Biological Products / pharmacology
  • Biological Products / therapeutic use
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Proliferation* / drug effects
  • Cell Survival / drug effects
  • DNA Damage / drug effects
  • DNA Topoisomerases, Type I / metabolism
  • Humans
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / pathology
  • Porifera / chemistry
  • Topoisomerase I Inhibitors / pharmacology
  • Topoisomerase I Inhibitors / therapeutic use
  • Zebrafish*

Substances

  • Antineoplastic Agents
  • DNA Topoisomerases, Type I
  • Topoisomerase I Inhibitors
  • Biological Products